Shots:
- The NDA submission is based on P-I study of adult patients, the P-II NAVIGATE trial in adult and adolescent patients and the P- I/II pediatric SCOUT trial. These trials evaluated Larotrectinib in 20+ different histologies of solid tumors with NTRK fusion
- The therapy is already approved in several countries under the brand name Vitrakvi, including the US, EU, and Japan. The regulatory filing in other countries are underway or planned
- Larotrectinib is a highly selective TRK inhibitor exclusively designed to treat tumors that have an NTRK gene fusion
Click here to read full press release/ article | Ref: Bayer | Image: Shanghai Daily
The post Bayer Seeks Approval of Larotrectinib for Advanced Solid Tumors in China first appeared on PharmaShots.
